|
International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. The London-based investor in biotech and life science companies has appointed Schroders Capital Management Switzerland, part of Schroders PLC, as its investment manager. IBT has committed an initial £10 million to the partnership, around 4% of its current portfolio value. This will be used to increase IBT’s holding of unquoted stock over time. As of September 26, IBT estimated its exposure to unquoted companies at 8.4%, mainly through private funds, and specifically two funds managed by SV Health Partners. Most of the firm’s assets are held in quoted stock. IBT does not expect the Schroders Capital tie-up to impact existing holdings, but said: ‘It is the board’s intention that over the long-term the partnership will provide shareholders with access to a portfolio of innovative earlier-stage companies through unquoted funds, diversified by underlying manager, vintage and geography.’ The investment firm noted its new manager’s ‘strong relationships with leading healthcare and biotechnology managers across North America, Europe, and Asia,’ and pointed to Schroders Capital investing about £3.5 billion in the sector over the past 25 years. IBT’s goal is to benefit from ‘access to differentiated opportunities that have the potential to significantly improve global healthcare outcomes,’ it added. In exchange, the firm will pay Schroders Capital a 0.9% per annum management fee, based on the asset value of IBT’s investment in the partnership, in addition to an annual charge of £25,000 for administrative costs. Aggregate fees for a single year will be capped at 0.25% of IBT’s net asset value, it said. IBT shares traded 0.2% lower at 776.44 pence on Thursday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
